<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, there are no effective antiviral drugs or vaccines for prevention of EV-A71 infection. A previous study has suggested the potential of the VP1 protein as a candidate antigen for an EV-A71 vaccine 
 <xref rid="B42" ref-type="bibr">
  <sup>42</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B43" ref-type="bibr">
  <sup>43</sup>
 </xref> . A recombinant VP1 protein of the EV-A71 virus has been produced in 
 <italic>Escherichia coli</italic> , yeast and the baculovirus system 
 <xref rid="B42" ref-type="bibr">
  <sup>42</sup>
 </xref>
 <sup>-</sup>
 <xref rid="B44" ref-type="bibr">
  <sup>44</sup>
 </xref> . Vaccination with a VP1 protein vaccine can induce neutralizing antibodies to protect against EV-A71 infection 
 <xref rid="B42" ref-type="bibr">
  <sup>42</sup>
 </xref>
 <sup>-</sup>
 <xref rid="B44" ref-type="bibr">
  <sup>44</sup>
 </xref> . However, another study showed that vaccination with a recombinant VP1 induced a lower titer of EV-A71-specific IgG antibodies than inoculation with the inactivated virus 
 <xref rid="B42" ref-type="bibr">
  <sup>42</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B43" ref-type="bibr">
  <sup>43</sup>
 </xref> . Although recombinant VP1 vaccine can elicit similar levels of neutralizing antibodies, it provided effective protection only at a low challenge dose of EV-A71 
 <xref rid="B42" ref-type="bibr">
  <sup>42</sup>
 </xref> .
</p>
